An FDA committee will discuss Moderna boosters. Here's what to expect

This week marks another potential watershed moment for Moderna Inc.'s Covid-19 vaccine: A key advisory committee to the U.S. Food and Drug Administration is set to meet to discuss so-called "booster shots." Cambridge-based Moderna (Nasdaq: MRNA) has built a case for a booster shot — a third shot identical to each of the first two in the series — over the last several months. In September, the biotech noted that so-called "breakthrough cases" of Covid-19, or cases in patients who have received…